Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures.
From the U.S. FDA-approved label for Cisplatin. Full label: DailyMed.
Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
From the U.S. FDA-approved label for Cisplatin. Full label: DailyMed.
Cisplatin is administered by slow intravenous infusion. Aluminum reacts with cisplatin, causing precipitate formation and a loss of potency. Metastatic Testicular Tumors The usual cisplatin dose for the treatment of testicular cancer in combination with other approved chemotherapeutic agents is 20 mg/m 2 IV daily for 5 days per cycle.
Directions from the U.S. FDA-approved label for Cisplatin — your doctor or pharmacist may advise differently.
Cisplatin is contraindicated in patients with pre-existing renal impairment. Cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. Cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum containing compounds.
Excerpt from the U.S. FDA-approved label for Cisplatin. Talk to a pharmacist or doctor before use.
Cisplatin produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics. The serum creatinine, blood urea nitrogen (BUN), creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, cisplatin should not be given more frequently than once every 3 to 4 weeks (see ADVERSE REACTIONS ). Elderly patients may be more susceptible to nephrotoxicity (see PRECAUTIONS, Geriatric Use ).
Warnings and precautions excerpt from the U.S. FDA-approved label for Cisplatin — not a complete list. Talk to a pharmacist or doctor before use.
Nephrotoxicity Dose-related and cumulative renal insufficiency, including acute renal failure, is the major dose-limiting toxicity of cisplatin. Renal toxicity has been noted in 28% to 36% of patients treated with a single dose of 50 mg/m 2. It is first noted during the second week after a dose and is manifested by elevations in BUN and creatinine, serum uric acid and/or a decrease in creatinine clearance.
Excerpt from the U.S. FDA-approved label for Cisplatin — not a complete list. Talk to a pharmacist or doctor about side effects.
8 brands · 5 makers in the NepalDoc catalog — see the full Cisplatin guide →
Conditions Store at 20° to 25°C (68° to 77°F). Do not refrigerate. Protect from light. Sterile, Nonpyrogenic, Preservative-free. This container closure is not made with natural rubber latex.
Storage information from the U.S. FDA-approved label for Cisplatin.
What is Cisplatin?
Cisplatin 10mg Injection is a Cisplatin medicine made by Pfizer Ltd. It comes as 10mg Injection.
What is the generic name of Cisplatin?
The generic name of Cisplatin is Cisplatin.
Which brands of Cisplatin are available in Nepal?
8 brands of Cisplatin are listed in the NepalDoc catalog, from 5 makers — including Cisplatin 50mg Injection, Cytoplatin 50mg Injection, Kemoplat 10mg Injection, Kemoplat 50mg Injection, Platicin 10mg Injection, Platicin 50mg Injection.
What are the side effects of Cisplatin?
Nephrotoxicity Dose-related and cumulative renal insufficiency, including acute renal failure, is the major dose-limiting toxicity of cisplatin. Renal toxicity has been noted in 28% to 36% of patients treated with a single dose of 50 mg/m 2.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.
